Compare Datadog Inc (DDOG) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs GSK plc — how do they compare? Datadog Inc trades at $293 (market cap $98.31B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: Datadog Inc and GSK plc are close in size by market cap, and GSK plc pays a 3.9% dividend while Datadog Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and GSK plc for 93 Days on average.
| DDOG | GSK | |
|---|---|---|
Market Cap | $98.31B | $91.88B |
Volume | 2,936,660 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $288.15 | $61.18 |
52-Week Low | $102.62 | $43.24 |
Typical Hold Time | 76 Days | 93 Days |
Enterprise Value | $94.61B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $290.26, up 6.97% with strong bullish momentum approaching 52-week highs. The stock shows robust revenue growth reaching $3.43B in 2025, though profitability metrics remain mixed with a high P/E ratio of 547.6. Recent earnings beats and accelerating enterprise customer expansion support positive sentiment, while technical indicators show the stock trading near resistance at $288 with strong moving average support.
Investment outlook remains positive given strong analyst consensus (83% buy ratings) and AI-driven growth catalysts, though elevated valuation and negative cash flow trends present risks. The $276.10 consensus price target suggests limited upside from current levels, requiring continued execution on enterprise expansion and margin improvement to justify premium valuation.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
